Company Seoulin Bioscience Co.,Ltd.

Equities

A038070

KR7038070009

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sector Other Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
8,720 ^KRW	-1.80%		-2.57%	-5.22%

Mar. 20	Seoulin Bioscience Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Seoulin Bioscience Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Seoulin Bioscience Co., Ltd is a Korea-based company engaged in the developing and manufacturing of basic equipment for bio research. The Company mainly engages in research and development of reagents, such as deoxyribonucleic acid (DNA) chips, which are used for gene therapy, clinical diagnosis, organs transplantation and biopsy; stem cells, which are used for treatment of incurable diseases, Alzheimer disease and others, and next-generation biotechnology drugs. The company supplies its products under the brand name MyLab. It also imports bio research equipment from Thermo Fisher, Affymetrix, Sarstedt and others, and markets in the domestic market. In addition, the Company engages in the real estate rental business.

Number of employees: 100

KRW in Million	2022	Weight	2023	Weight	Delta
Biotechnology 96.4 %	97,930	95.6 %	86,378	96.4 %	-11.80%
Healthcare 3.6 %	4,476	4.4 %	3,262	3.6 %	-27.11%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 100.0 %	102,406	100.0 %	89,569	100.0 %	-12.54%

Managers	Title	Age	Since
Mi-Ok Kang CEO	Chief Executive Officer	54	-
Eul-Moon Hwang CEO	Chief Executive Officer	72	84-04-01
Hee-Yong Jung SAM	Sales & Marketing	53	-
Gwang-Gi Ahn AUD	Comptroller/Controller/Auditor	71	-
Ki-Taek Choi AUD	Comptroller/Controller/Auditor	65	-

Members of the board	Title	Age	Since
Eul-Moon Hwang CEO	Chief Executive Officer	72	84-04-01
Ki-Taek Choi AUD	Comptroller/Controller/Auditor	65	-
Mi-Ok Kang CEO	Chief Executive Officer	54	-
Geum-Ryong Lee BRD	Director/Board Member	70	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	8,900,676	6,056,549 ( 68.05 %)	339,052 ( 3.809 %)	68.05 %

Name	Equities	%	Valuation
Eul-Moon Hwang 27.31 %	2,432,790	27.31 %	18 M ₩
SEOULIN BIOSCIENCE CO.,LTD. 3.897 %	347,162	3.897 %	3 M ₩
Si-yang Gil 1.238 %	110,267	1.238 %	799 410 ₩
Mi-Ok Kang 0.0963 %	8,576	0.0963 %	62 174 ₩
Gwang-Gi Ahn 0.0235 %	2,096	0.0235 %	15 196 ₩
Dimensional Fund Advisors Ltd. 0.0134 %	1,195	0.0134 %	8 663 ₩
DFA Australia Ltd. 0.0100 %	891	0.0100 %	6 460 ₩

Name	Equities	%	Valuation
SEOULIN BIOSCIENCE CO.,LTD. 3.90%	347,162	3.90%	2,516,845 $

SeouLin Bioscience Co., Ltd.

4/F, Korea Bio Park A-Dong 700 Daewangpangyo-ro

13488, Seongnam-si

http://www.seoulin.co.kr

address Seoulin Bioscience Co.,Ltd.(A038070)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
SEOULIN BIOSCIENCE CO.,LTD.	-5.22%	53.9M
IQVIA HOLDINGS INC.	+0.67%	42.4B
LONZA GROUP AG	+44.30%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.55%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-21.66%	18.96B
MEDPACE HOLDINGS, INC.	+29.96%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.57%	11.95B
UNITED THERAPEUTICS CORPORATION	+16.03%	11.32B
BIO-TECHNE CORPORATION	-4.80%	11.55B

Other Biotechnology & Medical Research